Skip to Main Content

Sage Therapeutics said Tuesday that an experimental pill designed to alleviate depression with a two-week course of therapy was successful in a large clinical trial involving patients with major depressive disorder.

The Sage drug, called zuranolone, demonstrated a statistically significant, anti-depressive benefit compared to a placebo. The positive results are a comeback win for Sage and its efforts to develop zuranolone for several different depressive disorders. The drug failed a similar study in December 2019.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment